Atossa Therapeutics (NASDAQ:ATOS) Rating Reiterated by Cantor Fitzgerald

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports.

Several other equities analysts have also commented on the company. StockNews.com raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. HC Wainwright upped their target price on Atossa Therapeutics from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Finally, Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.00 to $6.25 and gave the stock a “buy” rating in a research report on Thursday, June 6th.

Atossa Therapeutics Stock Performance

NASDAQ:ATOS opened at $1.13 on Thursday. The stock has a market cap of $142.11 million, a price-to-earnings ratio of -4.71 and a beta of 1.19. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31. The business’s 50-day simple moving average is $1.43 and its 200 day simple moving average is $1.21.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. On average, equities research analysts predict that Atossa Therapeutics will post -0.23 EPS for the current year.

Insider Transactions at Atossa Therapeutics

In other Atossa Therapeutics news, Director Jonathan Finn bought 25,000 shares of Atossa Therapeutics stock in a transaction dated Wednesday, April 10th. The stock was bought at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the acquisition, the director now directly owns 25,000 shares of the company’s stock, valued at $44,250. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Atossa Therapeutics

Institutional investors have recently bought and sold shares of the stock. PFG Investments LLC bought a new position in Atossa Therapeutics during the first quarter valued at about $43,000. Cetera Advisors LLC bought a new position in Atossa Therapeutics during the first quarter valued at about $72,000. Virtu Financial LLC bought a new position in Atossa Therapeutics during the first quarter valued at about $151,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Atossa Therapeutics during the third quarter valued at about $98,000. Finally, Vanguard Group Inc. raised its holdings in Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after buying an additional 78,269 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.